Depomed names new CEO, directors in deal with activist Starboard
Reuters
Published Mar 28, 2017 06:00PM ET
Updated Mar 28, 2017 06:10PM ET
Depomed names new CEO, directors in deal with activist Starboard
(Reuters) - Depomed Inc (O:DEPO) reached a deal with activist investor Starboard Value LP to name a new chief executive officer and two other directors to its board.
The drugmaker's shares fell nearly 6 percent to $13.39 in extended trading after the company also forecast lower-than-expected first quarter sales.
Depomed said former Bayer (DE:BAYGN) Healthcare chief Arthur Higgins would take over as CEO from James Schoeneck, following his resignation.
"We are pleased to have reached an agreement to work with Depomed and believe that Arthur Higgins is an excellent choice to lead Depomed," said Gavin Molinelli, partner of Starboard.
Depomed named Higgins, Molinelli and William McKee, a former chief financial officer of Barr Pharmaceuticals LLC, as board directors.
Starboard said in September that it wanted to oust the drugmaker's board. However, Starboard and Depomed struck a truce in October, with the hedge fund getting three seats on the board.
The investor had criticized Depomed's board over alleged governance deficiencies and urged it to explore a sale.
The drug company said on Tuesday it expects first-quarter sales of $95 million to $100 million. Analysts on average were expecting sales of $114.6 million, according to Thomson Reuters I/B/E/S.
Earlier in the day, U.S. Democratic Senator Claire McCaskill asked the nation's top opioid drugmakers, including Depomed, for internal estimates of the risk of abuse, addiction and overdose of opioids, as lawmakers step up efforts to tackle the deadly opioid crisis.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.